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Imaging individual protein aggregates to follow aggregation and determine
the role of aggregates in neurodegenerative disease
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A B S T R A C T
Protein aggregates play a key role in the initiation and spreading of neurodegenerative disease but have been difficult to study due to their low abundance and
heterogeneity, in both size and structure. Fluorescence based methods capable of detecting and characterising single aggregates have recently been developed and
can be used to measure many important aggregate properties, and can be combined with sensitive assays to measure aggregate toxicity. Here we review these
methods and discuss recent examples of their application to determine the molecular mechanism of aggregation and the detection of aggregates in cells and
cerebrospinal fluid. The further development of these methods and their application to the aggregates present in humans has the potential to solve a major problem in
the field and allow the identification of the key toxic species that should be targeted in therapies.
1. Introduction
The assembly of protein monomers, into small soluble aggregates
(oligomers), to ultimately form insoluble fibrils is fundamentally im-
portant. It is a process that can occur for most proteins, under suitable
conditions, and it also plays a major role in the initiation and spreading
of protein aggregates through the brain in neurodegenerative diseases
such as Alzheimer's and Parkinson's disease [1]. Studying this process in
the test-tube, in cells or in humans, is challenging since only a small
fraction of the protein forms oligomers at any given time; typically<
1%. These oligomers are heterogeneous in both size and structure
unless strategies are used to enrich one oligomeric species [2,3]. Fur-
thermore, it is important to be able to relate the structure of the ag-
gregates to their properties, particularly biologically relevant properties
such as cytotoxicity or ease of degradation. Some aggregates may not be
toxic at all, while others of a specific structure and size might be highly
toxic. Approaches capable of imaging and measuring the properties of
individual aggregates have been developed to address these problems
and will be discussed in this review.
While it is possible to perform controlled aggregation reactions of
proteins in the test-tube, such as the aggregation of alpha-synuclein
(αS) associated with Parkinson's disease and amyloid-β (Aβ) and tau
associated with Alzheimer's disease (AD), extrapolation of this data to
what happens during the course of disease is challenging. This is be-
cause it can take decades to develop these diseases compared to the
hours to few days to perform the experiments, creating a time gap. This
means that it is important to study both the kinetics and
thermodynamics of the aggregation process, since it is not clear in
which regime the disease process occurs. Furthermore, the test-tube
experiments are generally performed at concentrations that are higher
than those in vivo by several orders of magnitude, so one needs to be
able either to perform experiments at physiological concentrations,
picomolar in the case of Aβ oligomers, or to extrapolate back these
conditions. In addition, during the aggregation process in vivo, the
monomers are also modified by, for example, truncation or phosphor-
ylation so that the fibrils formed consist of largely or entirely chemi-
cally modified monomers. Thus there are three gaps that need to be
bridged between test-tube and in vivo experiments: a time, concentra-
tion and reality gap.
One strategy to deal with these issues and bridge these gaps is to
develop methods that can directly image and characterise the in-
dividual protein aggregates in human samples. Another strategy is to
develop kinetic and thermodynamic models of the aggregation process,
which fit the experimental data obtained at higher concentrations, and
then extrapolate this data to longer times and lower concentrations that
are not accessible experimentally. This can be combined with a bottom-
up approach where studies are performed on systems of increasing
complexity; such as in the studying the aggregation of post-translational
modified proteins or performing experiments in the presence of two
proteins or in the presence of chaperones, which are present in vivo and
act to inhibit aggregation. Given the large number of possible variables,
these experiments need to be informed by the variables that have been
shown to be important in animal models and humans.
There have been recent reviews of single molecule studies of protein
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aggregation [4,5]. This review will focus on what can be learnt from
studies of protein aggregates at the level of individual aggregates using
fluorescence, and the advantages and disadvantages of this approach. It
will critically discuss what we have learnt to date about protein ag-
gregation and neurodegenerative disease, and what needs to be done in
the future to gain new insights into the role of protein aggregates in
neurodegenerative disease in humans.
2. The single aggregate approach
Single protein aggregates can be detected by fluorescence-based
methods, atomic force microscopy or electron microscopy. This review
will focus only on fluorescence based methods. The main concept be-
hind single molecule fluorescence is that a single fluorophore either
covalently or transiently bound to the molecule of interest can emit 1-
10 million photons before photobleaching, so that a detectable fluor-
escence signal can be generated from one fluorophore on a single
protein molecule. If transient binding is used, it is possible to observe
molecules for long periods of time, which opens up the possibility to do
biochemical reactions on individual molecules.
Fluorescence based methods can be performed on aggregates in
solution or immobilised to a surface (Fig. 1). Solution based methods,
generally using a confocal microscope set-up, avoid any bias in surface
affinity but provide shorter observation times (< 1ms) while surface
based methods, generally using a total internal reflection fluorescence
(TIRF) microscopy set-up allow longer observation times (seconds to
hours). There are several different strategies to distinguish monomer
from oligomers. This can be done by labelling each monomer with the
same fluorophore and distinguishing monomer from oligomer based on
fluorescence intensity or the number of photobleaching steps [6], since
oligomers should have multiple photobleaching steps. A method with
higher discrimination is to label monomers with either red or blue
fluorophores. Oligomers can be detected by the presence of both
fluorophores in the same spatial region, when imaging, or the emission
of simultaneous red and blue fluorescence if performed in solution
[7,8]. This method can be extended to detect intramolecular Fluores-
cence Resonance Energy Transfer (FRET) between a donor and accep-
tors fluorophore on different monomers in the same oligomer [9]
(Fig. 1A). The extent that FRET occurs can also provide information
about the structure of the oligomer in certain cases.
An alternative strategy is to use molecules that specifically bind to
oligomers of certain structure or composition. These can be antibodies,
nanobodies or aptamers either labelled with a dye or which have a DNA
strand attached (Fig. 1B and C). Transient binding of the com-
plementary imaging strand to the DNA on the antibody allows imaging
of the aggregate over long periods of time, a method called DNA PAINT
(point accumulation for imaging in nanoscale topography) [10]. Al-
ternatively, dyes like Thioflavin T can be used, that have significantly
Fig. 1. Principles of single aggregate measure-
ments. A) Fluorophore labelled monomer can un-
dergo intermolecular FRET between a donor and
acceptor fluorophore when aggregates are formed.
This allows aggregates to be distinguished from
monomer. Detection of coincident red and blue
fluorescence allows the number of aggregates to be
counted and their relative size to be estimated by
comparing the fluorescence intensity to that of the
monomer. The extent of FRET can also be measured
which provides information about the compaction of
the aggregate and if one or multiple species are
present. B)Total internal reflection fluorescence mi-
croscopy can be used to detect aggregates on a glass
coverslipusing the transient binding nature of dyes
such as Thioflavin T or the pentameric form of
formyl thiophene acetic acid (pFTAA), whose
quantum yield increases significantly when bound to
beta sheet structures in the aggregates. C) The tran-
sient binding of a fluorophore labelled DNA imaging
strand to the docking strand on an aptamer that
binds aggregates allows single molecule localisation
to be performed. This enables aggregates of Aβ to be
imaged at super-resolution. The scale bar is 500 nm.
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higher affinity for aggregates than monomer [11]. Thioflavin T re-
versibly binds to oligomers with beta sheet structure. Moreover, several
of the molecules developed for Positron-emission tomography (PET)
imaging of protein aggregates in the human brain are also fluorescent
and can also be used for aggregates imaging [12].
2.1. What can be measured?
In the case when the monomer is labelled with a fluorophore, the
first thing that can be measured is the fraction of all monomers that
form oligomers; hence the concentration of oligomers can be de-
termined. It is also possible to get information about relative oligomer
size, compared to a monomer, from the intensity of the fluorescence
signal. This is the apparent oligomer size since it is estimated from the
fluorescence signal and relies on there be no significant fluorophore
quenching in the oligomer. The extent of FRET (FRET efficiency) can
also provide information about oligomer structure, particularly if ag-
gregates with different structures are present [9]. In the case when
specific oligomers are detected using molecules that transiently bind,
then the number of these oligomers can be determined, although here
calibration samples will be needed to convert this into a fraction or
concentration.
It is also possible to work in a regime where only a single fluor-
ophore is bound to an oligomer at any time. In this case it is possible to
localise the position of this fluorophore to 20–40 nm depending on the
intensity of the signal. Multiple rounds of imaging of individual ag-
gregates then allows images of the aggregate to be obtained at
20–40 nm resolution allowing their size to be determined. This ap-
proach can be used for both surface immobilised aggregates and can
also be performed in fixed cells [13].
2.2. Obtaining more information about aggregates
As well as measuring the number and concentration of the ag-
gregates in a sample, it is possible to obtain a great deal more in-
formation. In general, samples need to be diluted to picomolar con-
centrations for single molecule experiments. Unstable species can
dissociate in this dilution step so if performed rapidly, using micro-
fluidic devices, it is possible to measure these unstable species [14] and
also detect species more rapidly [15]. However, it is probably the
species that are stable at these low concentrations that are more re-
levant to the disease pathogenesis, given the concentration of oligomers
is low in vivo, for example the concentration of Aβ42 oligomers is 1–10
pM in human (CSF) [16]. Dilution into buffers of high salt or low salt to
measure the stability of the oligomers and monitoring their stability
over time is a strategy that can be used to measure their relative sta-
bility and hence resolve different species. It is also possible to add en-
zymes such as proteinase K (PK) and then measure which oligomer
remain and which are degraded after a certain time, to distinguish
oligomers based on their PK resistance.
More information is also available from dyes that bind transiently to
the aggregates. Use of environmentally sensitive dyes allows one to
measure the surface hydrophobicity of aggregates [17,18]. For ex-
ample, Nile red's fluorescence spectrum shifts depending on its hydro-
phobic environment. Since this dye also binds transiently to aggregates
it can be used to simultaneously measure aggregate size and surface
hydrophobicity. The extent of modulation of the dye fluorescence can
also be used to probe the extent that the aggregate structure is ordered
and distinguish fibrillary aggregates [19].
3. Oligomer properties
Obtaining information about the number, size and structure of the
oligomers present in samples is important. However, some oligomers
might be highly toxic to cells and some might be non-toxic, so it is vital
to have sensitive assays to measure parameters associated with
oligomer toxicity and the interaction of oligomers with putative re-
ceptors. Currently there are no assays sensitive enough to measure the
toxicity of a single oligomer, so experiments need to be performed on a
solution where the oligomers have been characterized and the toxicity
is measured and then a second sample, where the number or structure
of the oligomers is altered, is used in order to determine which species
are more toxic.
Since the physiological concentration of oligomers is in the low
picomolar range it is important to develop assay that work in this
concentration range. An important point is that the gap between cells is
only about 50 nm in the brain [20] so that the volume round a cell
10 μm in diameter is only 15 fL and contains 0.01 molecules at an oli-
gomer concentration of 1 pM. The oligomer concentration needs to be
100-fold higher than physiological levels for there to be one oligomer
per cell. Even at 20 nM oligomers, the estimated concentration of Aβ
oligomers above a fibril [21], there are only 200 oligomer per cell and
not all of these oligomers will bind to receptors in the cell membrane.
Therefore, even if the local concentration is higher than physiological
levels, these estimates suggest that toxic effects will need to be medi-
ated by single oligomers, certainly at the start of the disease. This
means that the effect of the oligomers needs to be caused by binding a
single receptor or occur via mechanism that does not involve specific
binding to receptors. In contrast, for experiments performed in vitro, at
a fixed oligomer concentration there is a much larger volume of oli-
gomers per cell and hence many more oligomers can interact with a cell
over extended times causing effects that might not occur under more
physiological conditions.
Using sensitive imaging techniques, it is possible to directly observe
the binding of fluorophore labelled oligomers to fluorophore labelled
receptors and hence directly determine the extent of binding as a
function of oligomer concentration. This is important since in some
cases oligomers may effect receptor function by indirect mechanisms
rather than directly binding to the receptor. For these experiments to be
possible the density of the receptor on the cell surface needs to be 1
receptor per μm2 or lower so that individual receptors can be visualised
using diffraction limited imaging (Fig. 2A). In principle higher receptor
densities could be studied using super-resolution imaging, although this
has not been done to date to our knowledge. The receptor needs to be
labelled in a manner that does not significantly perturb function using
antibodies or genetic encoding of the label. Despite the potential of this
method to directly measure the affinity of oligomers for putative re-
ceptors in the cell membrane, so far it has only been applied to the
interaction between Aβ oligomers and prion protein [22].
We recently developed an ultra-sensitive assay to measure the
ability of oligomers to permeabilise a lipid membrane to allow the entry
of calcium ions [23] (Fig. 2B). Calcium dysregulation is commonly
observed in neurodegenerative disease, so this assay provides one
measure of oligomer toxicity. The assay is based on thousands of lipo-
somes arrayed on a surface. Aggregates added in solution can per-
meabilise the lipid membrane, resulting in calcium ions from the bath
entering the liposome. Calcium ion entry is detected by the presence of
a calcium ion binding dye present in the liposome using fluorescence
imaging in a TIRF microscopy mode. Generally, there is only a small
increase in calcium ions showing that the aggregates do not form per-
manent pores in the membrane. At the end of the experiment iono-
mycin is added to measure the intensity of the fluorescence signal when
each liposome is filled calcium ions. This assay allows the sensitive
quantification of the number of lipid membrane permeabilising ag-
gregates present in the sample. This is based on averaging the mea-
surements from many individual liposomes and we have shown that it
can detect oligomers at concentrations as low as 1 pM [23]. This assay
can potentially be made more sensitive and selective by optimising the
lipid composition for the oligomers of interest.
A related assay has recently been developed that uses giant plasma
membrane vesicles which detects both the binding of oligomers of
amylin to the vesicle membrane and entry of green fluorescent protein
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into the vesicle [24]. FRET with low numbers of donor and acceptor
labelled monomer was used to show that the oligomers that cause
permeation are dynamic, contain hundreds of monomers and cause
permeation by two mechanisms. Using enriched αS oligomers a recent
study using NMR showed that the enriched oligomer species that was
most effective at membrane disruption was lipophilic, to facilitate
membrane binding, and had rigid beta-sheet structure that inserted into
the membrane to disrupt its structure [25]. This study provides new
insights into the molecular basis of oligomer induced toxicity.
4. Limitations of current methods
Since the aggregates exist in a range of different sizes and structures
one issue is whether all oligomers are detected in any given study. Only
if experiments are performed with dye labelled protein can one be
confident that all aggregates present are detected and this is still only
the stable oligomers that are still present at dilution to picomolar
concentrations for single molecule imaging. However, these stable ag-
gregates are arguably the most relevant under a physiological setting.
For unlabelled aggregates one approach would be to use a range of
aggregate specific reagents to ensure the majority of aggregates are
detected. Sizing using fluorescence intensity is only approximate and
the lack of model samples of known stoichiometry makes it difficult to
calibrate the method, so direct imaging of the aggregates using super-
resolution to determine their size is a better approach. AFM has recently
been demonstrated to also be a useful method to more accurately
measure aggregate size and follow dynamics [26–28], so use of high
resolution AFM would nicely complement fluorescence based methods.
Expanding the number of measurements that can sensitively determine
properties of the aggregates related to their cellular toxicity would also
be highly desirable, especially on cells. Sensitive assays have been de-
veloped to detect the production of cytokines during T-cell triggering.
Since the same cytokines are also produced during neuroinflammation,
it would be interesting to explore application of these methods to ag-
gregate induced inflammation [29].
5. What are the key questions?
Before reviewing what has been done using these methods it is
useful to discuss the following issues: what are the key questions that
need to be addressed; what questions can currently be addressed and
what advances are needed to bridge the gap between these two sets of
questions? In our view, the key questions are which are the aggregates
responsible for the initiation and spreading of neurodegenerative dis-
eases through the human brain? By what mechanism do aggregates
form from monomer in the brain? By what molecular mechanisms do
they damage and kill neurons? By what mechanisms do they spread
from neuron to neuron? Which are the key species that should be tar-
geted in therapy?
So far the questions that have been addressed to a greater or lesser
extent by single aggregate studies are what is the molecular mechanism
for aggregation of pure proteins in the test-tube; which species are
formed and which are toxic and by what mechanism? Such experiments
provide a baseline for the range of protein aggregates that might be
formed in vivo and their potential mechanisms of toxicity. However,
they fail to deal with the potential complexity in vivo where there are
significant post-translational modifications and there are different un-
folded proteins present that can potentially interact with each other
over time [30,31]. This in turn highlights the need to develop methods
to detect and characterise the real protein aggregates present in humans
with neurodegenerative diseases such as Alzheimer's and Parkinson's
disease.
6. Examples of studies of single aggregates to date using
fluorescence methods
Since single aggregate studies have been comprehensively reviewed
very recently [4], we will go through some recent examples of the
different types of experiments that have been performed done from our
own work, and discuss what insights they provide into the questions
above.
6.1. The aggregation pathway for αS
The protein αS self-assembles into small oligomeric species and
subsequently into amyloid fibrils that accumulate and proliferate
during the development of Parkinson's disease. We labelled αS at po-
sition 90 close to the NAC region of the protein with either a donor or
acceptor fluorophore [9]. Oligomers could be detected selectively de-
tected by FRET between the donor and acceptor fluorophores in an
oligomer and we found that distinct species with high and low FRET
could be detected. The low FRET species was sensitive to PK degrada-
tion while the high species was PK resistant.
We performed experiments over a range of monomer concentrations
from 0.5 to 140 μM and found that the data could be fitted to a kinetic
model with slow unimolecular conversion steps between low FRET
(globular) oligomers and high FRET compact oligomers [32]. These
compact oligomers converted to fibril-like oligomers which then went
onto form fibrils by monomer addition (Fig. 3). We found that the high
FRET species were significantly more effective at inducing production
of reactive oxygen species in neuronal cells than the low FRET species.
We could use this kinetic model to predict the effectiveness of aggregate
seeds at inducing aggregation when entering a cell, assuming that the
cell just acted as a container of αS molecules. In this case a large
number of seeds needed to enter a cell in order for the rate of
Fig. 2. Oligomer toxicity A) Different size aggregates can bind receptors in the
cell membrane leading to signalling. This can be detected by imaging if the
receptor and aggregate are both fluorophore labelled since the fluorescence
signals will co-localise. Alternatively, aggregates can bind non-specifically to
the cell membrane which leads to a fluorescence signal that does not co-localise
with the labelled receptor and can induce membrane permabilisation. B) A li-
posome assay using small surface immobilised liposomes, containing a Calcium
binding dye can sensitively detect membrane permeabilisation by oligomers.
Calcium ion entry from the bath into the liposome leads to increased fluores-
cence in the liposome that can be sensitively detected by total internal reflec-
tion fluorescenece microscopy.
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aggregation to be enhanced. Since smaller number of aggregates could
induce production of ROS this suggested that cell stress may contribute
to spreading. However, if nucleation was prevented in the cellular en-
vironment, so that no aggregation occurred then a single seed would be
able to induce aggregation of the αS in a cell. Experiments with Nile red
imaging of the surface hydrophobicity also showed that the oligomers
are structurally distinct from fibrils, being more hydrophobic which in
combination with their smaller size probably contribute to their toxicity
[17].
Overall, these experiments showed that there is rapid formation of
globular oligomers that then slowly convert into more toxic and PK
resistant beta-sheet rich oligomers. These in turn grow and convert into
fibril-like oligomers, which can then go onto form fibrils. In contrast to
the millisecond to second times associated with protein folding, the
time scale for these key conversion steps is 10 h.
We extended these studies to study the aggregation of pathological
mutants of αS [33]. Certain missense mutations in the gene encoding
for αS induce early-onset forms of the disease. It has been suggested
that these variants might have an inherent tendency to produce high
concentrations of oligomers during aggregation, although a direct ex-
perimental evidence is still missing. We compared wild-type αS to
A53T, A30P and E46K mutants and compared both the aggregation
kinetics and the structural properties of the ensemble of oligomers
generated. We found that the kinetics of oligomer formation correlates
with the natural tendency of each variant to acquire beta-sheet struc-
ture. Moreover, A53T and A30P showed significant differences in the
averaged FRET efficiency and only one of the two types of oligomers
formed compared to the wild-type oligomers. Importantly, we found
similar concentrations of oligomers during the lag-phase of the ag-
gregation of wild-type and mutated αS, suggesting that the properties of
the ensemble of oligomers generated during self-assembly might be
more relevant than their absolute concentration for triggering neuro-
degeneration. Other properties of the oligomers that might be more
important such as their structure, stability or removal rates.
6.2. Tau aggregation
We also used single-molecule fluorescence to study the aggregation
of the repeat domain of tau (K18), which forms the core region of
neurofibrillary tangles found in AD. Our initial kinetic analysis reveals
that aggregation proceeds via monomeric assembly into small oligo-
mers, and a subsequent slow structural conversion step before fibril
formation [34]. Using this approach, we have been able to
quantitatively determine how specific disease associated mutations
alter the aggregation energy landscape. More recently, we extended
these studies and distinguished several subpopulations of oligomers
with different stability, by diluting into buffers with different ionic
strength [35]. We followed the evolution of these different oligomeric
species during aggregation reactions as a function of temperature and
concentration.
Employment of techniques from chemical kinetics reveals that the
two largest populations are structurally distinct from fibrils and are
both kinetically and thermodynamically unstable. The first population
is in rapid exchange with monomers and held together by electrostatic
interactions. The second is kinetically more stable, dominates at later
times, and is probably off-pathway to fibril formation. These more
stable oligomers may contribute to other oligomer induced effects in
the cellular environment, for example, by overloading protein quality
control systems. We also showed that the shortest growing filaments
remain suspended in aqueous buffer and thus comprise a third, smaller
population of transient oligomers with cross-β structure. Our data
showed that a diverse population of oligomers of different structures
and half-lives are formed during the aggregation reaction with the great
majority of oligomers formed not going on to form fibrils.
6.3. Generality of protein aggregation mechanism
Our studies of αS and tau show that distinct oligomeric species are
formed, and a conversion step is needed to form fibril-like aggregates. A
recent study of the yeast prion protein Ure2 demonstrates the formation
of two separate oligomer species with different kinetic and structural
properties [36]. Both oligomers are unstable and predominantly dis-
sociate and are on-pathway to fibril formation. This is very similar to
the aggregation mechanism for αS but with the formation of oligomeric
species with decreased stability.
One issue with the study of tau aggregation is the need to induce
aggregation using heparin, unlike in cells where it can occur sponta-
neously resulting in highly phosphorylated tau fibrils. While it is pos-
sible that some of the species are observed due to the use of heparin,
these experiments also highlighted that the most frequently occurring
oligomers are transient in nature. A significant energetic rearrangement
would be needed for these to convert to growth-competent, fibril-like
oligomers, which are present at far lower concentrations. This means
that a wide range of oligomeric species can be present at the start of the
aggregation process, with different properties, and only as the ag-
gregation proceeds fibril and fibril-like oligomeric species become the
Fig. 3. General pathway for aggregation of proteins to form amyloid fibrils.Monomers form oligomers which undergo a slow structural conversion to fibril-like
oligomers which then can grow by monomer addition into long fibrils. Monomers can also assemble into off-pathway oligomers. The relative number of the different
species depends on the forward and backward rate constants and can be modified by the addition of chaperones or antibodies.
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dominant species. A wider range of species might be expected to be
formed if the aggregation reaction occurs at lower concentrations and
longer times than in these relatively short few hour experiments. There
will be more time to explore more of the energy landscape although this
regime has not been explored to date experimentally.
Both synuclein, tau and Ure2 show a generic mechanism with the
formation of oligomers that convert into fibril-like oligomers, with the
possibility of the formation of off-pathway oligomers (Fig. 3). The re-
lative rates of the forward and backward reaction determine whether
the oligomers are transient or stable. While this is the mechanism in
solution, it is likely to be modified by many of the molecules present in
the cell. This could be either by changing the reaction rate constants or
by adding additional pathways or the presence of additional surfaces
such as lipid membranes.
6.4. Increasing complexity
Protein aggregation occurs in the complex environment of the cell,
which contains lipid membranes and chaperones which can alter the
rate and pathway of aggregation. To study the effect of a particular
cellular component, one can perform experiments in the presence of
different concentrations. We have done such experiments for chaper-
ones and lipids known to be important in neurodegenerative disease.
It is proposed that αS forms soluble alpha-helical multimers in
healthy neurons [37]. We made αS multimers in the test-tube using
arachidonic acid (ARA), one of the most abundant fatty acids in the
brain, and characterized them by a combination of bulk experiments
and single-molecule FRET measurements [38]. The data suggested that
ARA-induced oligomers are alpha-helical, resistant to fibril formation,
more prone to disaggregation, enzymatic digestion and degradation by
the 26S proteasome, and lead to lower neuronal damage and reduced
activation of microglia compared to the oligomers formed in the ab-
sence of ARA. These multimers can be formed at physiologically-re-
levant concentrations, and pathological mutants of αS form less mul-
timers than wild-type αS. Our work provides strong biophysical
evidence for the formation of alpha-helical multimers of αS in the
presence of a biologically relevant fatty acid, which may have a pro-
tective role with respect to the generation of beta-sheet toxic structures
during αS fibrillation.
We also studied the effect of the extracellular chaperones Clusterin
and α2-macroglobulin on the aggregation of αS, using one fluorophore
on the chaperone and a different fluorophore on the αS [39]. We found
that both chaperones tended to bind small oligomers (< 5 αS mono-
mers) in an approximate equimolar ratio. Oligomers containing>5 αS
monomers were observed to be associated with proportionally less
chaperone, suggesting that the number of chaperone-accessible binding
sites on the αS oligomer surface does not increase linearly with the
number of αS monomers in an oligomer. Clusterin exhibits differential
binding to αS oligomers that may be related to structural differences
between two previously described forms of αS oligomers, in particular
the high hydrophobicity of smaller oligomers. The binding of both
chaperones appears to shield the surface hydrophobicity present on the
oligomers and reduces the ability of the oligomers to permeabilize lipid
membranes and prevents an oligomer-induced increase in ROS pro-
duction in cultured neuronal cells.
A similar study investigated the binding of the chaperone heat shock
protein 70 (Hsp70) to tau aggregates [40]. We found that Hsp70 has a
much higher affinity for oligomers and fibrils, than monomer, with the
affinity increasing with aggregate size. Binding inhibited both the ag-
gregation reaction, specifically the elongation and reduced aggregate
toxicity.
Lastly we have studied how nanobodies alter the aggregation of ɑS
[41]. One widely explored therapeutic strategy for treatment of neu-
rodegenerative disease is the use of antibodies, although a detailed
molecular-level mechanism of the action of such species remains elu-
sive. We characterized αS aggregation in the presence of two ɑS-specific
single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which
bind to the highly accessible C-terminal region of αS. We found that
both nanobodies inhibit the formation of αS fibrils. Furthermore, we
demonstrated that nanobody binding promotes a rapid conformational
conversion from more stable oligomers to less stable oligomers of αS,
leading to a dramatic reduction in oligomer-induced cellular toxicity.
This is in contrast to our previous studies of Hsp70 or chaperones where
binding did not alter the oligomer structure. This result suggests that
the C-terminal region is more buried in the stable, beta sheet containing
oligomers so that binding to this region by nanobodies causes conver-
sion into less stable and less toxic oligomers. How much this effect is
due to the smaller size of the nanobodies compared to conventional
antibodies and how much to targeting the C-terminal region needs to be
further investigated. However, it is an important finding since it pro-
vides a potential mechanism to rapidly convert toxic aggregates into
less toxic and less stable aggregates, reducing the toxic load on neurons.
6.5. Thermodynamics of aggregate formation
There have been few studies of the thermodynamics of aggregate
formation, in contrast to the large number of studies performed on the
aggregation of the key proteins associated with neurodegenerative
disease (Aβ, tau and αS). Even basic information about the critical
aggregation concentration at which monomer is in equilibrium with
fibrils has not been firmly established for these proteins. Furthermore,
there is little literature on the cellular concentration of these proteins
making it difficult to apply a quantitative approach to the problem of
aggregate formation. There is also little information on the thermo-
dynamics of oligomer formation, although this is more understandable
given the technical issues in detecting small aggregates.
Multiple isoforms of aggregation-prone proteins are present under
physiological conditions and have the propensity to assemble into co-
oligomers with different properties from self-oligomers [42], but this
process has not been quantitatively studied to date. We have in-
vestigated the Aβ peptide, associated with AD, and the aggregation of
its two major isoforms, Aβ40 and Aβ42, using a statistical mechanical
modelling approach in combination with test-tube single-molecule
fluorescence measurements [21]. We found that at low concentrations
of Aβ, corresponding to its physiological abundance, there is little free
energy penalty in forming co-oligomers, suggesting that the formation
of both self-oligomers and co-oligomers is possible under these condi-
tions.
A model was used to predict the oligomer concentration and size at
physiological concentrations of Aβ and suggests the mechanisms by
which the ratio of Aβ42 to Aβ40 can affect cell toxicity [21]. An in-
creased ratio of Aβ42 to Aβ40 raises the fraction of oligomers con-
taining Aβ42, which can increase the hydrophobicity of the oligomers
and thus promote deleterious binding to the cell membrane and in-
crease neuronal damage. Our results suggest that co-oligomers are a
common form of aggregate when Aβ isoforms are present in solution
and may potentially play a significant role in AD.
The more complex in vivo environment is potentially affected by
numerous extrinsic factors such as the presence of small molecules and
proteins, lipid surfaces, altered pH or ionic strength. Therefore, the
underlying assumption of thermodynamic equilibrium may not be
correct. However, our model predicted the oligomer concentration
observed in human CSF, of about 1 pM concentration at a total Aβ
concentration of 1nM. Even though the amount of Aβ42 in the CSF is
generally observed to decrease in AD, our model predicts that this has
little effect on the total oligomer concentration, because their popula-
tion is largely dominated by Aβ40 oligomers. This may provide a simple
explanation for why most diagnostic tests for AD to date based on de-
tecting the Aβ oligomer concentration in CSF observe little significant
difference between controls and AD patients.
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6.6. Prion-like spreading
There is mounting evidence that suggests that the protein assem-
blies involved in various neurodegenerative diseases, including ag-
gregated tau, are capable of self-sustaining amplification, allowing the
propagation of pathological assemblies along connected brain cells,
resulting in progression from restricted areas to large numbers of brain
regions [43–45]. This process is commonly referred to as prion-like
spreading, given its similarities to prion disease. The spreading requires
that on entry into the cytoplasm of cells, tau assemblies can seed the
aggregation of native monomers, thereby initiating the formation of
additional aggregates, which can be released and spread to neigh-
bouring cells. Both tau filaments from recombinant protein as well as
filamentous material extracted from tau mouse models or AD brains
have been shown to act as seeds in various model systems and initiate
the spreading of tau pathology.
On a molecular level, to achieve propagation of protein aggregates
through the brain, an amplification of seeds is required by fragmenta-
tion or surface templated aggregation. We characterised the aggrega-
tion kinetics of unlabelled full-length wild-type and mutant P301S tau
using the luminescent conjugated oligothiophene (pFTAA) and TIRF
imaging of the aggregates [46]. We found that the aggregate length
increased rapidly over the first 24 h and then, once the monomer was
largely used up, the length of the aggregates decreased over the next
4 weeks due to fragmentation.
This experiment provided direct evidence for fragmentation and
hence amplification of tau aggregates in vitro. The elongation and
fragmentation rate constants that were measured suggested that prion-
like spreading could explain the rate of propagation of tau aggregates
through the human brain in AD. According to this study, the time
needed for one aggregate to double into two aggregates is of the order
of several months to years in humans which means that aggregates must
be present in neurons for this period of time. This provides a simple
explanation of why propagation is via neurons, since they do not divide
and cell division would dilute any aggregates formed.
This initial work has only been performed on 4 repeat tau. So it will
be interesting to measure the elongation and fragmentation rate con-
stants for 3 repeat tau to see how they compare with 4 repeat tau and
also perform co-aggregation experiments with 3 and 4 - repeat tau. In
AD, the aggregates formed contain both 3 and 4 repeat tau, while in
tauopathies the aggregates can contain only 3 or 4 repeat tau. The
structure of 3repeat tau fibrils from a patient with Pick's disease has
recently been determined [47] and differs from the structure of the fi-
brils from an AD patient [48] supporting the concept that different
prion strains have different fibrillar structure and hence would be ex-
pected to propagate at different rates.
6.7. In cells
Imaging the formation of aggregates in cells and which sub-cellular
organelles they interact with is a significant advance. This should allow
the molecular mechanism of aggregate induced toxicity to be probed
and reveal what cellular mechanisms fail and lead to aggregate for-
mation. We have combined DNA PAINT with an amyloid specific ap-
tamer or aggregate specific antibody, and shown that this technique is
able to detect and super-resolve a range of aggregated species, in-
cluding those formed by αS and Aβ [13]. We used this method to image
the endogenous protein aggregates formed in neurons with 40 nm
spatial resolution. In our initial experiments we found that neuronal
cells derived from a Parkinson's patient with 3 copies of the SNCA gene
contain a larger number of protein aggregates than those from healthy
control. We also used DNA PAINT to show that αS oligomers, added
exogenously, bound specifically to ATP synthase, by performing si-
multaneous imaging using an antibody to ATP synthase [49]. This in-
teraction was confirmed by the use of a proximity ligation assay. Si-
milar experiments were performed with antibodies to an outer
mitochondrial protein, TOMM20, and an inner mitochondrial mem-
brane protein. These experiments show the potential of DNA PAINT
imaging of aggregates in cells.
6.8. Characterising the real aggregates in humans
We have used the methods described here to perform an initial
study of the soluble aggregates present in humanCSF from patients who
are affected with AD. In these experiments, we measured the number of
aggregates using Thioflavin T and their ability to permeabilise a lipid
membrane [50]. We have also tested the effectiveness of a single-chain
nanobody raised against the Aβ peptide, the extracellular chaperone
Clusterin, and bapineuzumab (a humanized monoclonal antibody that
was recently used in an unsuccessful AD drug trial) at reducing the
Ca2+ influx induced by samples of CSF. We found that both control and
AD CSF contained comparable numbers of soluble aggregates, unlike
our study of Parkinson's disease CSF where there was a significant in-
crease compared to controls [11]. In addition, both AD and control CSF
caused detectable membrane permeabilisation and calcium ion entry.
This could be blocked by Clusterin and a nanobody to Aβ, but the ba-
pineuzumab was ineffective unless used at high concentrations. This
study shows that toxic aggregates are present in CSF, providing a
method to test potential therapies without costly clinical trials. The
changes that take place during progression of AD are either more subtle
in terms of aggregate composition or structure or that they are so di-
luted from the affected brain region that there are too small to be de-
tectable when extracted using a lumbar puncture. If this is the case, it
will be necessary to study samples derived from processed human brain
tissue samples.
7. Future directions
Arguably one of the biggest problems in the field has been the dif-
ficulty in detecting and characterising the protein aggregates associated
with neurodegenerative disease. This is due to their low concentration
and high heterogeneity. The recent development of methods with single
aggregate sensitivity solves this issue by opening up the possibility of
characterising aggregates in cells, human brain tissue and biofluids
such as CSF, and following the aggregation process in cells. More ag-
gregate specific binding agents, such as conformational specific anti-
bodies, will be needed to make it possible to better characterise the
composition of the different aggregates to complement the measure-
ment of their size, number and location.
Our lab is starting to use rationally designed antibodies for oligo-
mers which allow the targeting of any region on the protein, without
the need for it to be immunogenic [51]. An outstanding problem is to be
able to identify which of the aggregates are toxic and by what me-
chanism. This can be done by measuring the toxicity of samples with a
different combination of aggregates with different structures and cor-
relating the different structures with the changes in toxicity. Alter-
natively, one could perform experiments on aggregates separated on
the basis of a particular property such as size or mass. However, other
sensitive toxicity assays need to be developed to complement the
membrane permeabilisation assay, since aggregates can be toxic to cells
by a number of different mechanisms. In principle, direct imaging of an
aggregate binding to a labelled receptor would allow one to identify the
both the toxic aggregate and the pathway, although this will require
screening of all possible receptors. The ability to detect the aggregates
in humans and measure their disease relevant biological activity should
enable potential therapeutic strategies to be tested and optimised prior
to costly clinical trials.
Overall one can hope, with some justifications, that the main tools
are now in place to start to determine the key aggregate species re-
sponsible for the initiation and spreading of neurodegenerative disease
and hence start to rationally design and test therapies that target these
toxic species.
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